Identifying and optimizing human endometrial gene expression signatures for endometrial dating.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Spath K
  • Ferrando M
  • Kohls G
  • García-Velasco JA
  • Seli E
  • Wells D

Grupos

Abstract

STUDY QUESTION: What are the key considerations for developing an enhanced transcriptomic method for secretory endometrial tissue dating? SUMMARY ANSWER: Multiple gene expression signature combinations can serve as biomarkers for endometrial dating, but their predictive performance is variable and depends on the number and identity of the genes included in the prediction model, the dataset characteristics and the technology employed for measuring gene expression. WHAT IS KNOWN ALREADY: Among the new generation of transcriptomic endometrial dating (TED) tools developed in the last decade, there exists variation in the technology used for measuring gene expression, the gene makeup and the prediction model design. A detailed study, comparing prediction performance across signatures for understanding signature behaviour and discrepancies in gene content between them, is lacking. STUDY DESIGN, SIZE, DURATION: A multicentre prospective study was performed between July 2018 and October 2020 at five different centres from the same group of clinics (Spain). This study recruited 281 patients and finally included in the gene expression analysis 225 Caucasian patients who underwent IVF treatment. After preprocessing and batch effect filtering, gene expression measurements from 217 patients were combined with artificial intelligence algorithms (support vector machine, random forest and k-nearest neighbours) allowing evaluation of different prediction models. In addition, secretory-phase endometrial transcriptomes from gene expression omnibus (GEO) datasets were analysed for 137 women, to study the endometrial dating capacity of genes independently and grouped by signatures. This provided data on the consistency of prediction across different gene expression technologies and datasets. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial biopsies were analysed using a targeted TruSeq (Illumina) custom RNA expression panel called the endometrial dating panel (ED panel). This panel included 301 genes previously considered relevant for endometrial dating as well as new genes selected for their anticipated value in detecting the secretory phase. Final samples (n = 217) were divided into a training set for signature discovery and an independent testing set for evaluation of predictive performance of the new signature. In addition, secretory-phase endometrial transcriptomes from GEO were analysed for 137 women to study endometrial dating capacity of genes independently and grouped by signatures. Predictive performance among these signatures was compared according to signature gene set size. MAIN RESULTS AND THE ROLE OF CHANCE: Testing of the ED panel allowed development of a model based on a new signature of 73 genes, which we termed 'TED' and delivers an enhanced tool for the consistent dating of the secretory phase progression, especially during the mid-secretory endometrium (3-8 days after progesterone (P) administration (P + 3-P + 8) in a hormone replacement therapy cycle). This new model showed the best predictive capacity in an independent test set for staging the endometrial tissue in the secretory phase, especially in the expected window of implantation (average of 114.5 ± 7.2 h of progesterone administered; range in our patient population of 82-172 h). Published sets of genes, in current use for endometrial dating and the new TED genes, were evaluated in parallel in whole-transcriptome datasets and in the ED panel dataset. TED signature performance was consistently excellent for all datasets assessed, frequently outperforming previously published sets of genes with a smaller number of genes for dating the endometrium in the secretory phase. Thus, this optimized set exhibited prediction consistency across datasets. LARGE SCALE DATA: The data used in this study is partially available at GEO database. GEO identifiers GSE4888, GSE29981, GSE58144, GSE98386. LIMITATIONS, REASONS FOR CAUTION: Although dating the endometrial biopsy is crucial for investigating endometrial progression and the receptivity process, further studies are needed to confirm whether or not endometrial dating methods in general are clinically useful and to guide the specific use of TED in the clinical setting. WIDER IMPLICATIONS OF THE FINDINGS: Multiple gene signature combinations provide adequate endometrial dating, but their predictive performance depends on the identity of the genes included, the gene expression platform, the algorithms used and dataset characteristics. TED is a next-generation endometrial assessment tool based on gene expression for accurate endometrial progression dating especially during the mid-secretory. STUDY FUNDING/COMPETING INTEREST(S): Research funded by IVI Foundation (1810-FIVI-066-PD). P.D.-G. visiting scientist fellowship at Oxford University (BEFPI/2010/032) and Josefa Maria Sanchez-Reyes' predoctoral fellowship (ACIF/2018/072) were supported by a program from the Generalitat Valenciana funded by the Spanish government. A.D.-P. is supported by the FPU/15/01398 predoctoral fellowship from the Ministry of Science, Innovation and Universities (Spanish Government). D.W. received support from the NIHR Oxford Biomedical Research Centre. The authors do not have any competing interests to declare.

© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Datos de la publicación

ISSN/ISSNe:
0268-1161, 1460-2350

HUMAN REPRODUCTION  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
284-296
Factor de Impacto:
1,993 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • TED; artificial intelligence; endometrial dating; endometrial factor; endometrial progression; gene expression signatures; infertility; machine learning; menstrual cycle; transcriptomic stratification

Campos de estudio

Proyectos asociados

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL

CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

CONTRATO POST FSE (RIO HORTEGA)

CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

CD15/00058 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2016

TRAMIENTO COMBINADO DE VITAMINA D CON AGNRH SOBRE EL CRECIMIENTO DE LOS MIOMAS UTERINOS

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI15/00312 . INSTITUTO DE SALUD CARLOS III . 2016

Alternativas para la Preservacion de la fertilidad en pacientes con leucemia aguda. Maduracion in vivo mediante xenotransplante.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

GRISOLIAP/2018/029 . CONSELLERIA DE EDUCACION . 2018

Estudio de las modificaciones epigenéticas como posibles dianas terapéuticas para tratar los miomas uterinos.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI18/00323 . INSTITUTO DE SALUD CARLOS III . 2019

Searching for the pathological window of implantation and its therapeutic targets for its clinical translation for precision medicine in reproduction.

Investigador Principal: PATRICIA DÍAZ GIMENO

PI19/00537 . INSTITUTO DE SALUD CARLOS III . 2020

Contrato PFIS: Predoctorales de formación en investigación en salud. Elena Juarez

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

FI19/00110 . INSTITUTO DE SALUD CARLOS III . 2020

ESTUDIO CLÍNICO PILOTO PARA EVALUAR EL EFECTO DE LA VITAMINA D SOBRE EL TAMAÑO DE LOS MIOMAS EN MUJERES CON DEFICIENCIA DE VITAMINA D.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

IIS-COL-2018-01 . 2019

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.

Investigador Principal: VICENTE PAYÁ AMATE

M12-671

Estudio del efecto del estrés en la ventana de implantación y su influencia en el éxito reproductivo

Investigador Principal: PATRICIA DÍAZ GIMENO

FPU19/03247 . MINISTERIO DE CIENCIA E INNOVACION . 2020

Perfiles transcriptómicos y secretómicos tras cultivo extendido de embriones humanos euploides y aneuploides para el cromosoma 21

Investigador Principal: FRANCISCO DOMÍNGUEZ HERNÁNDEZ

PI20/00405 . INSTITUTO DE SALUD CARLOS III . 2021

Estudio de los mecanismos moleculares de compactación y polarización en el embrión humano: implicaciones en la viabilidad embrionaria

Investigador Principal: MARÍA JOSÉ DE LOS SANTOS MOLINA

PI20/00523 . INSTITUTO DE SALUD CARLOS III . 2021

Contrato PFIS 2020. Pablo García Acero

Investigador Principal: PATRICIA DÍAZ GIMENO

FI20/00085 . INSTITUTO DE SALUD CARLOS III . 2021

Contratos Miguel Servet I 2020. Patricia Díaz Gimeno.

Investigador Principal: PATRICIA DÍAZ GIMENO

CP20/00118 . INSTITUTO DE SALUD CARLOS III . 2021

IMPACTO DE LA INFECCIÓN POR SARS-COV-2 (COVID-19) EN EL ENDOMETRIO HUMANO: EVALUACIÓN IN VITRO DE LOS EFECTOS DE HIDROXICLOROQUINA (HCQ) UTILIZANDO ORGANOIDES ENDOMETRIALES HUMANOS.

Investigador Principal: IRENE CERVELLÓ ALCARAZ

2020-268-1_CRC FERRING COVID_CERVELLO . FERRING PHARMACEUTICALS A/S . 2020

PREPARACION DE FOLICULOS ANTRALES, PREVIA A FECUNDACION IN VITRO TIPO ICSI, EN PACIENTES CON BAJA RESPUESTA OVARICA. ENSAYO CLINICO PROSPECTIVO ALEATORIZADO CONTROLADO.

Investigador Principal: CÉSAR DÍAZ GARCÍA

FOLLPRIM

IMPACT OF SERUM PROGESTERONE CONCENTRATION ON THE DAY OF EMBRYO TRANSFER IN MODIFIED NATURAL CYCLES AND STIMULATED CYCLES ON ONGOING PREGNANCY RATE.

Investigador Principal: MARÍA ELENA LABARTA DEMUR

IVI-PRO-2019-02

PLASMA RICO EN PLAQUETAS PROCEDENTE DE CORDÓN UMBILICAL PARA EL TRATAMIENTO DE PATOLOGÍAS ENDOMETRIALES (ENDOMETRIO FINO/ SÍNDROME DE ASHERMAN/ ATROFIA ENDOMETRIAL): UN ESTUDIO PILOTO.

Investigador Principal: MÓNICA ROMEU VILLARROYA

2001-FIVI-002-IC . 2021

Cita

Compartir